Chitosan oligosaccharides attenuate loperamide-induced constipation through regulation of gut microbiota in mice. (1st February 2021)

• Record Type: Journal Article
• Authors: Zhang, Xiaoyu; Yang, Huabing; Zheng, Junping; Jiang, Nan; Sun, Guangjun; Bao, Xinkun; Lin, Aizhen; Liu, Hongtao
• Is Part Of: Carbohydrate polymers. Volume 253(2021)
• Publication Date: 2021-02-01
• Subjects: AQP3 aquaporin 3 -- BAs bile acids -- CA cholic acid -- COS chitosan oligosaccharides -- DCA deoxycholic acid -- ENaC-β epithelial sodium channel beta -- IL-1β interleukin-1beta -- KEGG Keyoto Encyclopedia of Genes and Genomes -- LC/GC-MS liquid chromatography/gas chromatography-mass spectrometer -- LOP loperamide -- NLRP3 nod-like receptor pyrin domain containing 3 -- PICRUSt Phylogenetic Investigation of Communities by Reconstruction of Unobserved States -- RT-qPCR real-time quantitative PCR -- SCFAs short-chain fatty acids -- TCA taurocholic acid -- TCDCA taurochenodeoxycholic acid -- TDCA taurodeoxycholic acid -- TLR4 toll-like receptor 4 -- TNF-α tumor necrosis factor-alpha -- TUDCA tauroursodeoxycholic acid -- TαMCA tauro-α-murocholicacid -- TβMCA tauro-β-murocholicacid -- UDCA ursodeoxycholic acid -- 5-HT 5-hydroxytryptamine; Chitosan oligosaccharides (COS) -- Constipation -- Gut microbiota -- Short chain fatty acids (SCFAs) -- Bile acids (BAs); Polysaccharides -- Periodicals; Polysaccharides -- Periodicals; Polysaccharides -- Périodiques; Electronic journals; 547.78
• DOI: 10.1016/j.carbpol.2020.117218
• Languages: English
• ISSNs: 0144-8617

Abstract

Graphical abstract: Highlights: Chitosan oligosaccharides (COS) attenuated constipation in loperamide-induced mice. COS reshaped the structure of disbalanced gut microbiota in constipated mice. COS regulated production of intestinal metabolites in constipated mice. COS improved constipation through the regulation of gut microbiota in mice. Abstract: This study was designed to explore the improvement of chitosan oligosaccharides (COS) on constipation through regulation of gut microbiota. Here, we proved that COS treatment profoundly boosted intestinal motility, restrained inflammatory responses, improved water-electrolyte metabolism and prevented gut barrier damage in constipated mice induced by loperamide. By 16S rDNA gene sequencing, the disbalanced gut microbiota was observed in constipated mice, while COS treatment statistically reversed the abundance changes of several intestinal bacteria at either phylum, family and genus levels, which partly led to the balance in production of intestinal metabolites including bile acids, short-chain fatty acids and tryptophan catabolites. In addition, COS failed to relieve the constipation in mice with intestinal flora depletion, confirming the essentiality of gut microbiota in COS-initiated prevention against constipation. In summary, COS can ameliorate the development of loperamide-induced constipation in mice by remodeling the structure of gut microbial community.